Publications

5491 Results

Interrupting Endocrine Therapy to Attempt Pregnancy After Breast Cancer

Authors
AH Partridge;S Niman;M Ruggeri;F Peccatori;H Azim;M Colleoni;C Saura;C Shimizu;A Saetersdal;J Kroep;A Mailliez;E Warner;V Borges;F Amant;A Gombos;A Kataoka;C Rousset;S Borstnar;J Takei;J Lee;J Walshe;M Ruiz Borrego;HCF Moore;C Saunders;V Bjelic-Radisic;S Susnjar;F Cardoso;K Smith;T Ferreiro;K Ribi;K Ruddy;R Kammler;S El-Abed;G Viale;M Piccart;L Korde;A Goldhirsch;R Gelber;O Pagani
Journal / Conference
New England Journal of Medicine May 4;388(18):1645-1656
Year
2023
Research Committee(s)
Breast and Cancer Survivorship
PMID
PMID37133584
PMC
PMC10358451
Study Number(s)
CTSU/A221405

Do I Know You? Patient Privacy and Consent in the Age of Social Media

Authors
J Sommers;A Mercurio
Journal / Conference
JCO Oncology Practice Feb;19(2):Feb;19(2):
Year
2023
PMID
PMID36480776

Alliance A031902 (CASPAR): A randomized, phase 3 trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) in first-line metastatic castration-resistant prostate cancer (mCRPC)

Authors
A Rao;G Heller;C Ryan;D Vanderweele;L Lewis;A Tan;C Watt;R Chen;M Kohli;P Barata;B Gartrell;R Grubb;A Dueck;Y Wen;M Morris
Journal / Conference
J Clin Oncol 41, 2023 (suppl 6; abstr TPS277); ASCO GU Cancers Symposium (Feb 16-18, 2023, San Francisco, CA), poster
Year
2023
Research Committee(s)
Genitourinary

Evaluating the impact of stratification, sample size, and randomization ratio on the power of randomized Phase 2 clinical trials

Authors
A Moseley;M LeBlanc;M Othus
Journal / Conference
Society for Clinical Trials (May 21-24, 2023, Baltimore, MD), poster
Year
2023
Research Committee(s)
Cancer Care Delivery

Randomized Phase II Trial of Olaparib + Pembrolizumab vs Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 (gBRCA1/2+) Mutations: SWOG S2001 NCT04548752

Authors
V Chung;K Guthrie;M Pishvaian;K Reiss;A Lowy;D Sohal;S Colby;E Sharon;C Allegra;E O'Reilly;E Chiorean;P Philip
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr TPS4198); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), TIP poster session
Year
2023
Research Committee(s)
Gastrointestinal
Study Number(s)
S2001

Nivolumab-AVD Improves Progression-Free Survival (PFS) Compared to Brentuximab Vedotin-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL), Results of SWOG S1826

Authors
A Herrera;M LeBlanc;S Castellino;H Li;S Rutherford;A Evens;K Davison;A Punnett;D Hodgson;S Parsons;S Ahmed;C Casulo;N Bartlett;J Tuscano;M Mei;B Hess;R Jacobs;H Saeed;P Torka;B Hu;C Moskowitz;S Kaur;G Goyal;C Forlenza;A Doan;A Lamble;P Kumar;S Chowdury;B Brinker;N Sharma;A Singh;K Blum;W Macon;A Perry;A Kovach;L Constine;L Kostakoglu Shields;A Prica;R Little;M Shipp;M Crump;B Kahl;J Leonard;S Smith;J Song;K Kelly;JW Friedberg
Journal / Conference
Hematology Oncology Vol 41 Issue S2 Supplement; ICML (June 13 to June 17, 2023, Lugano, Switzerland), oral, plenary session
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
S1826

A “Functional Cure” May be Achievable in a Subset of Patients with Follicular Lymphoma treated with chemoimmunotherapy: 15-Year Follow-Up of Phase III SWOG-S0016

Authors
M Shadman;H Li;L Rimsza;J Leonard;M Kaminski;K Spier;A Gopal;S Dakhil;M LeBlanc;S Smith;JW Friedberg
Journal / Conference
Hematology Oncology Vol 41 Issue S2; ICML (June 13 to June 17, 2023, Lugano, Switzerland, oral
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
S0016

S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Authors
J Amengual;P Reagan;H Li;H Saeed;R Vaidya;J Unger;A Danilov;M LeBlanc;JW Friedberg;S Smith
Journal / Conference
Hematology Oncology Vol 41, Issue S2; ICML (June 13 to June 17, 2023, Lugano, Switzerland), publication only
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
S2207

SWOG 2114: A Randomized Phase II Trial of Consolidation Therapy following CD19 CAR T-cell Treatment for Relapsed/Refractory Large B-cell or Grade IIIB Follicular Lymphoma

Authors
B Hess;H Li;N Hossain;V Beylergil;C Sauter;M Hamadani;J Svoboda;A Major;B Kahl;J Leonard;S Smith;M LeBlanc;P Stiff;JW Friedberg
Journal / Conference
Hematology Oncology Vol 41, Issue S2; ICML (June 13 to June 17, 2023, Lugano, Switzerland), publication only
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
S2114

S1918: Phase II/III study of R-miniCHOP +/- oral azacitidine in participants age 75 years or older with diffuse large B cell and related lymphomas

Authors
E Brem;H Li;A Beaven;P Caimi;L Cerchietti;R Olin;NL Henry;H Dillon;R Little;M LeBlanc;B Kahl;J Leonard;JW Friedberg;S Smith
Journal / Conference
Hematology Oncology Vol 41 Issue S2; ICML (June 13 to June 17, 2023, Lugano, Switzerland), publication only
Year
2023
Research Committee(s)
Lymphoma
Study Number(s)
S1918